English (UK)
中文版- 1
- 2
Mr. Di Di
TransThera Biosciences is a Nanjing based biotech, founded in 2016, focusing on research and development of small molecules in oncology, inflammation, and cardiovascular diseases. Four assets have entered into global clinical development in past 4 years.
Nanjing TransThera Biosciences Co. Ltd.
VP, Strategy and BDDavid Dill
We have, by a wide margin, the safest and most effective nocturia drug. Nocturia leads to over 10,000 deaths per day and costs the US economy $215B/year in lost worktime and lower productivity. We have the only drug that treats low bladder capacity, which is an issue for 76% of nocturia sufferers. Our clinical trial results were 5x better than the first FDA approved nocturia drug and 2.5x better than the other FDA approved nocturia drug, both of which carry a black warning about a dangerous blood disorder and have other side effects. Of course these drugs treat polyuria rather than low bladder capacity, so they are not competitors for our drug.
Wellesley Pharmaceuticals, LLC
CEO & PresidentMr. DIMITAR DIMITROV
Micar Innovation is a drug discovery factory. The company has found a niche where it is able to create a large societal impact by improving the quality of life through discovery novel blockbuster drug molecules for a large class of diseases (Pipeline). Micar Innovation focuses on entire drug discovery process using improved structure based insilico drug design from scratch till Preclinical phase with advanced predictions of activity, selectivity and ADMET.
Micar Innovation (Micar21)
CEO
Martin Duenas
OniX invest in companies in two ways: (1) Directly through it OniX Venture Fund and (2) Indirectly through its OniX hub members (includes pharma, VC, PE, family offices and private foundations)
OniX Hub
Founder/CEOMr. Jean-Baptiste Duval
Henlius (2696.HK) is a leading biopharmaceutical company in China with the vision to offer high-quality, affordable and innovative biologics for patients worldwide with a focus on oncology and autoimmune diseases. Since its inception in 2010, Henlius has built an integrated and efficient global R&D platform with key facilities in Shanghai, Taipei and California, and commercial office in Frankfurt. The three R&D centers closely collaborate with each other to ensure a highly productive and cost-efficient R&D process.
Starting from biosimilar, Henlius presses forward with novel mAb products and immuno-oncology combination therapies with proprietary anti-PD-1 and PD-L1 mAbs as backbone. Henlius establishes a diversified product pipeline of biosimilars, bio-innovative drugs and combination therapies, and builds an integrated platform covering the whole product lifecycle including R&D, commercial-scale production and commercialization.
Keywords : Cancer, Oncology, Biologics, Biosimilar, BioInnovative, Biobetter, Monoclonal Antibody, Mabs, Tumors, Immuno oncology, PD1, PD-L1, EGFR, VEGF, HER2,
Starting from biosimilar, Henlius presses forward with novel mAb products and immuno-oncology combination therapies with proprietary anti-PD-1 and PD-L1 mAbs as backbone. Henlius establishes a diversified product pipeline of biosimilars, bio-innovative drugs and combination therapies, and builds an integrated platform covering the whole product lifecycle including R&D, commercial-scale production and commercialization.
Keywords : Cancer, Oncology, Biologics, Biosimilar, BioInnovative, Biobetter, Monoclonal Antibody, Mabs, Tumors, Immuno oncology, PD1, PD-L1, EGFR, VEGF, HER2,
Responsive Web Design powered by 